Zhengye Biotechnology Holding Limited (ZYBT)
| Market Cap | 636.23M |
| Revenue (ttm) | 26.11M |
| Net Income (ttm) | 2.79M |
| Shares Out | 47.39M |
| EPS (ttm) | 0.06 |
| PE Ratio | 168.65 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 171,103 |
| Open | 10.50 |
| Previous Close | 10.31 |
| Day's Range | 9.70 - 13.79 |
| 52-Week Range | 3.50 - 14.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ZYBT
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its products to Vietnam, Pakistan, and Egypt. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited. [Read more]
Financial Performance
In 2023, ZYBT's revenue was 211.65 million, a decrease of -18.68% compared to the previous year's 260.27 million. Earnings were 31.46 million, a decrease of -32.69%.
Financial numbers in CNY Financial StatementsNews
Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option
Jilin, China, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, developm...
U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline
Three very small Asian issuers and one blank check company listed in the US this past week, though the biggest headlines came from a sizable launch and notable new filings. Energy equipment and servic...
Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering
Jilin, China, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, developm...
Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering
Jilin, China, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufactur...
Zhengye Biotechnology's Growth Slows As It Seeks U.S. IPO
Zhengye Biotechnology Holding Limited has filed for a $20 million IPO to raise capital for its acquisition program and new development capabilities. The company's revenue has declined, but it still ma...
Chinese animal health company Zhengye Biotechnology Holding files for a $20 million US IPO
Zhengye Biotechnology Holding, a Chinese provider of veterinary vaccines with a focus on livestock, filed on Tuesday with the SEC to raise up to $20 million in an initial public offering.
Zhengye Biotechnology IPO Registration Document (F-1)
Zhengye Biotechnology has filed to go public with an IPO on the NASDAQ.